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esponsibility of InstAbstract Gram-negative pathogen–induced nosocomial infections and resistance are a most serious
menace to global public health. Qingfei Xiaoyan Wan (QF), a traditional Chinese medicine (TCM)
formula, has been used clinically in China for the treatment of upper respiratory tract infections, acute or
chronic bronchitis and pulmonary infection. In this study, the effects of QF on Pseudomonas aeruginosa–
induced acute pneumonia in mice were evaluated. The mechanisms by which four typical anti-
inﬂammatory ingredients from QF, arctigenin (ATG), cholic acid (CLA), chlorogenic acid (CGA) and
sinapic acid (SPA), regulate anti-inﬂammatory signaling pathways and related targets were investigated
using molecular biology and molecular docking techniques. The results showed that pretreatment with QF
signiﬁcantly inhibits the release of cytokines (TNF-α and IL-6) and chemokines (IL-8 and RANTES),
reduces leukocytes recruitment into inﬂamed tissues and ameliorates pulmonary edema and necrosis. In2
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Qingfei Xiaoyan Wan, a traditional Chinese medicine formula, ameliorates Pseudomonas aeruginosa–induced acute 213addition, ATG was identiﬁed as the primary anti-inﬂammatory agent with action on the PI3K/AKT and
Ras/MAPK pathways. CLA and CGA enhanced the actions of ATG and exhibited synergistic NF-κB
inactivation effects possibly via the Ras/MAPK signaling pathway. Moreover, CLA is speculated to target
FGFR and MEK ﬁrstly. Overall, QF regulated the PI3K/AKT and Ras/MAPK pathways to inhibit
pathogenic bacterial infections effectively.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It may be a challenge to clarify traditional Chinese medicine
(TCM) therapies because their mechanisms are usually unclear and
many ingredients in these herbal formula may exert their effects by
regulating multiple pathways and targets1. Recently, TCM has
been considered to highlight targets in interconnected pathways that
can be used to cure complex disease. The integration of TCM and
“network” pharmacology provides an innovative approach for TCM
theory of both reductionist and holistic medicine, and bridges
traditional application and modern drug discovery2,3. TCM was
widely used for the clinical treatment of infectious diseases for
thousands of years in China, and it is based on different philosophies
than those of Western medicine, which are based on antibiotics4.
Now, TCM has also played an important role in the prevention and
treatment of infection during several large respiratory disease
outbreaks, such as severe acute respiratory syndrome (SARS) and
acquired pneumonia5,6. Although the precise mechanisms of action
remain unclear from the perspective of modern medicine, a
therapeutic regimen combining Chinese and Western medicines
has gained acceptance because it reduces resistance and toxicity.
Qingfei Xiaoyan Wan (QF) is a pill derived from a classic TCM
prescription (Maxing Shigan decoction) and consists of eight
common Chinese herbal medicines, Herba Ephedra, Gypsum
Fibrosum, Pheretima, Fructus Arctii, Semen Lepidii, Bovis Cal-
culus, Semen Armeniacae Amarum and Cornu Saigae Tataricae.
QF is approved by the China Food and Drug Administration (No.
Z12020757) and has been used clinically for the treatment of
upper respiratory tract infection, acute bronchitis, acute exacerba-
tion of chronic bronchitis and pulmonary infection with excellent
clinical effects. In our previous studies, QF alleviates asthma and
has anti-inﬂammatory activities7,8. Four types of NF-κB inhibitors,
including arctigenin (ATG) derivatives, cholic acid (CLA) deriva-
tives, chlorogenic acid (CGA), and sinapic acid (SPA), were
screened9 In this study, these anti-inﬂammatory compounds were
quantiﬁed using an ultra-performance liquid chromatography
(UPLC) system. The effects of QF on Pseudomona aeruginosa–
induced lung infection in mice were investigated, and possible
synergetic anti-inﬂammatory mechanisms for suppressing bacterial
pneumonia by mutual regulation of the PI3K/AKT and Ras/
MAPK pathways were identiﬁed.2. Materials and method
2.1. Reagents and materials
ATG, SPA, CLA, CGA, arctiin, deoxycholic acid, glycocholic
acid and deoxyglycocholic acid were obtained from Yifang S&T(Tianjin, China). Enzyme-linked immunosorbent assay (ELISA)
assay kits of rat TNF-α, IL-6, IL-1β and RANTES, as well as
human intracellular proteins (total p38, JNK and ERK), were
obtained from Pierce/Endogen Co. (Rockford, Illinois, USA).
Human TNF-α was purchased from PeproTech (Rocky Hill, NJ,
USA). Dexamethasone (Dex) and levoﬂoxacin (LEV) were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Reagents for cell culture were obtained from Gibco BRL Life
Technologies (Rockville, MD, USA). The NF-κB luciferase
reporter plasmid pGL4.32 and Renilla luciferase reporter vector
plasmid pRL-TK were obtained from Promega Co. (Fitchburg,
WI, USA). The Lipofectamine 2000 transfection reagent was
obtained from Invitrogen (Carlsbad, CA, USA). The anti-IκB-α
antibody was obtained from Santa Cruz Biotechnology (San
Diego, CA, USA). The P. aeruginosa PAK strain, a clinical
isolate from the sputum of a patient suffering from bronchiectasis,
was provided by Professor Mingqiang Qiao (College of Life
Science, Nankai University, China). All other reagents used in this
study were of analytical grade.2.2. Preparation of QF and drugs
Commercial QF (batch No. 5230139) was donated by Tianjin
Zhongxin Pharmaceutical Group Co. Ltd., Darentang Pharmaceu-
tical Factory (Tianjin, China). The QF pills were powdered and
suspended in distilled water. The QF suspension and LEV were
directly diluted with physiological saline for administration to
mice. The QF suspension, Dex, ATG, CLA, CGA and SPA were
dissolved in dimethylsulfoxide (DMSO) for in vitro experiments,
and the ﬁnal concentration of DMSO added to the cells was less
than 0.1%.2.3. Animals and drug administration
Kunming mice (male, 18–22 g) were purchased from the Experi-
mental Animal Center of the National Institute for the Control of
Pharmaceutical and Biological Products (Beijing, China). Animal
treatment and maintenance were performed in accordance with the
Principle of Laboratory Animal Care (NIH Publication No. 85–23,
revised 1985), and the Animal Ethics Committee of Nankai
University approved the experimental protocol. All animals were
housed in separate cages with food and water freely available
under standard laboratory conditions of 23–26 1C with a 12 h
light/12 h dark cycle. Sixty mice were randomly allotted into six
groups, including an uninfected control group (Con) and ﬁve
P. aeruginosa infected groups as follows: model group (Mod),
positive control group (LEV) and low/medium/high dose QF
groups (QF-L/QF-M/QF-H). LEV (7.5 mg/kg/d) and three doses
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one week before P. aeruginosa challenge.
2.4. P. aeruginosa–induced acute lung inﬂammation
The acute lung inﬂammation challenge was performed as pre-
viously described10. The P. aeruginosa PAK strain was used in the
experiments and was grown in Luria-Bertani (LB) medium. When
necessary, the PAK strain was cultured in duplicate in LB medium
overnight, washed twice with phosphate-buffered saline (PBS),
resuspended and diluted to a ﬁnal concentration of
1 109 colony-forming units/mL. One week after drug adminis-
tration, all mice except the control group were challenged with
40 mL of intratracheal PAK suspension (approximately
4 107 colony-forming units/lung), after anesthetizing (50 mg/kg
sodium pentobarbital, i.p.). The control group was administered
the same volume of PBS via the same route.
2.5. Histopathological evaluation
Twenty-four hours after P. aeruginosa challenge, mice were
anesthetized by sodium pentobarbital (50 mg/kg, i.p.), and blood
samples were collected from the retro-orbital cavity. The serum
was separated and the supernatant was collected and stored at
20 1C for subsequent testing. The lungs were collected and
placed in 10% formalin for at least 1 week. The organs were
embedded in parafﬁn, sectioned and stained with hematoxylin and
eosin (HE). True color photographic images of the slices were
taken using a light microscope (Olympus CKX41, Japan).
2.6. Cell culture, transfection and NF-κB-luciferase assay
BEAS-2B, a cell line derived from human bronchial epithelial cells,
was obtained from the American Type Culture Collection (Rockville,
MD, USA) and cultured in RPMI-1640 medium supplemented with
10% fetal bovine serum and 1% penicillin-streptomycin at 37 1C
with 5% CO2 in a humidiﬁed incubator. After stimulation by drug
and TNF-α, the supernatants were collected for the detection of
cytokine and chemokine. Simultaneously, BEAS-2B cells were co-
transfected in 96-well plates with the NF-κB luciferase reporter
plasmid pGL4.32 and Renilla luciferase reporter vector plasmid
pRL-TK at 100 and 9.6 ng per well, respectively. Transfection was
performed for 24 h using Lipofectamine 2000 according to the
manufacturer's instructions. The cells were pretreated with drugs
before stimulation by human TNF-α (10 ng/mL) for 6 h. After
stimulation, the cells were washed, lysed and assayed for luciferase
activity using the Promegadual-luciferase reporter assay system
according to the manufacturer's instructions as previously reported9.
2.7. Chemokine, cytokine and intracellular proteins
measurements
Cytokines (TNF-α and IL-6), chemokines (IL-8 and RANTES)
and intracellular proteins (total p38, JNK and ERK) in the
supernatants of plasma, homogenized lungs, cells or cell lysates
were measured using commercial ELISA kits according to the
manufacturer's instructions. The absorbance of each sample was
measured at 450 nm using a Bio-Rad Model 680 microplate
reader. Cytokine, chemokine and intracellular protein levels were
determined from standard curves and are expressed in picograms
per milliliter.2.8. Western blot analysis
BEAS-2B cells were washed with ice-cold PBS and lysed using lysis
buffer (2% SDS, 10% glycerol, 62.5 mmol/L Tris–HCl buffer, pH 6.8)
for 10 min. A total of 30 μg protein from the cell lysates was
transferred to nitrocellulose membranes following separation on 10%
SDS-PAGE. The membranes were blocked in 5% skim milk solution
overnight, incubated with polyclonal anti-IκB-α antibody (1:500) at
4 1C for 4 h and then washed twice with Tween 20/Tris-buffered saline
(TTBS). The blots were subsequently incubated with a secondary
horseradish peroxidase-conjugated rabbit antibody for 1 h at room
temperature and then washed extensively with TTBS. Detection was
performed using an enhanced chemiluminescence kit (Amersham
Biosciences, Uppsala, Sweden) as described by the manufacturer,
followed by auto-radiography.
2.9. UPLC/Q-TOF-MS analysis
The quantitative analysis of anti-inﬂammatory compounds was
performed as previously described with slight modiﬁcations9. A
Waters Acquity UPLC System (Waters Co., Milford, MA)
equipped with a photodiode array detector and a Waters Q-TOF
Premier with an electrospray ionization (ESI) system (Waters MS
Technologies, Manchester, UK) was used. The system was
controlled using the MassLynx V4.1 software (Waters Co.). An
Acquity BEH C18 column (100 mm 2.1 mm, 1.7 μm, Waters
Co.) was used for the separation. The products were eluted on a
gradient of 0.1% v/v aqueous formic acid (mobile phase A) and
acetonitrile (mobile phase B). The mobile phase gradient was as
follows: 5% to 15% B from 0 to 3 min, 15% to 30% B from 3 to
13 min, 30% to 35% B from 13 to 15 min, 35% to 80% B from 15
to 20 min, 80% to 100% B from 20 to 22 min, and 100% to 5% B
from 22 to 24 min. The ﬂow was maintained at 5% B from 24 to
30 min. The ﬂow rate was set at 0.4 mL/min, and the column
temperature was 30 1C. The experimental conditions for the Q-
TOF-MS were the same as previously reported.
2.10. Quantitative real-time PCR
After stimulation by drugs (ATG, CLA, CGA or SPA) and TNF-α, the
total RNA was extracted from the BEAS-2B cells with TRIzol
(Invitrogen, CA, USA) according to the manufacturer's instructions.
The cDNA was synthesized using a High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, CA, USA). PCR ampliﬁcation
was performed and analyzed in triplicate using the GoTaqqPCRMaster
Mix (Promega), and the emission intensity from the BRYT Green was
detected with an iCycler detection system (Bio-Rad, Hercules, CA,
USA). The expression levels of each gene were normalized with the
internal reference gene, β-actin. The PCR primers for the Ras/MAPK
(p38, Jnk, Erk, Ras and Pkc) and PI3K/AKT pathway (Pi3k, Fak and
Jak2) were designed and shown in Table 1.
2.11. Target prediction and molecular docking
Anti-inﬂammatory candidate compounds were selected and their
structures were saved in mol2 format ﬁle, and placed into the
PharmMapper database (http://59.78.96.61/pharmmapper/) for tar
get prediction. Annotation and pathway analysis were performed
using the Kyoto Encyclopedia of Genes and Genomes (KEGG)
(http://www.genome.jp/kegg/). To further evaluate the selectivity
of targets, a series of candidate molecules were optimized using
Table 1 Primers and probes for real-time RT-PCR.
Gene Primers sequence
p38 Forward-50-TCCAGACCATTTCAGTCCATC-30
Reverse-50-CGTCCAACAGACCAATCACAT-30
Erk Forward-50-GCCCGAAACTACCTACAGTCTC-30
Reverse-50-CCGTTTATTGGGGTT-AAAGGTT-30
Jnk Forward-50-TGGGTATGGGCTACAAAGAGA-30
Reverse-50-TTCCTCACAGTTGGCTGAAGT-30
Fak Forward-50-ATCCCACACATCTTGCTGACTT-30
Reverse-50-GCATTCCTTTTCTGTCCTTGTC-30
Jak2 Forward-50-AAGCAGCAAGTATGATGAGCAA-30
Reverse-50-TCCCATGAATAAGGGTGTTTTC-30
Pi3k Forward-50-CCTGCTTTTGGAGTCCTATTGT-30
Reverse-50-ATCTGGTCGCCTCATTTGC-30
Ras Forward-50-GGGTGAAGGACTCGGATGAC-30
Reverse-50-ATGTAGGGGATGCCGTAGCT-30
Pkc Forward-50-TATGGAAAATCTGTGGACTGGTG-30
Reverse-50-CTTGGCTGGGTGTTTGGTC-30
β-actin Forward-50-GACAGGATGCAGAAGGAGAT-30
Reverse-50-TGCTTGCTGATCCACATCTG-30
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of the potential target proteins were obtained from the Protein Data
Bank (ID: 2R7B, 3V6R, 3WJ6, 3EQF, 4J8F, 4EFL and 4EKK,
http://www.rcsb.org/pdb). At this stage, the target structures were
preprocessed and prepared by deleting all water molecules and
hydrogen atoms were then added. Next, a grid box was generated
before docking. The PDBQT ﬁles of targets and ligands were
prepared using AutoDockTools. The center of the grids was placed
on the center of the mass of ligands. A genetic algorithm (GA) was
used to simulate ligand-receptor binding. The number of GA runs
was 30. The step size parameters of quaternion and torsion were
set to 30. For each compound, 30 independent runs were
performed. Default values were used for all other parameters.2.12. Statistical analysis
The data are expressed as the mean7standard deviation (SD) of at
least 3 independent experiments. One-way ANOVA and student's
t-test were used for statistical analysis. Differences were consi-
dered statistically signiﬁcant if the P value was less than 0.05.3. Results
3.1. Effects of QF on pulmonary histopathology and the
production of cytokines
To evaluate the effects of QF on acute lung inﬂammation, the cross-
sections of lung tissue of HE staining are shown in Fig. 1A. PAK strain
infection caused capillary congestion, obstruction of small airways by
lymphocytic inﬁltrates, and widened alveolar septa compared to the
structural integrity of the lung tissue in the control group. Pretreatment
with medium and high-dose QF signiﬁcantly reduced histological
injury, with less obstruction of small airways and recruitment of
inﬂammatory inﬁltrates (Po0.05 and Po0.01, respectively). However,
histological damage was not improved by low-dose QF. The evidence
indicated that medium and high-dose QF ameliorated P. aeruginosa–
induced lung infection in mice.TNF-α, a pro-inﬂammatory factor, activates the expression of many
other cytokines and chemotactic factors and induces severe pulmonary
tissue injury11. IL-6 is a representative cytokine that stimulates mucous
secretion and promotes the differentiation of B cells and the
cytotoxicity of T cells and mast cells12. IL-8 can induce immune cell
inﬁltration, and RANTES causes mononuclear leukocytes and eosino-
philic granulocytes to participate in inﬂammation13,14. After P.
aeruginosa challenge, levels of cytokines and chemokines in the
plasma and lung homogenate were measured by ELISA. TNF-α, IL-6,
IL-8 and RANTES were signiﬁcantly increased in both the plasma and
lung tissue after P. aeruginosa infection. As shown in Fig. 1,
pretreatment with low dose QF did not prevent the release of TNF-
α, IL-6, and RANTES; however, treatment at medium and high dose
QF decreased the production of these cytokines in different degrees
(Po0.05 and Po0.001, respectively). Only high dose QF decreased
the release of RANTES (Po0.05). These results were consistent with
the histological changes noted above.
3.2. Effects of QF on cytokine activation and IκB-α degradation
in bronchial epithelial cells
The effects of QF on the production of cytokines were also studied on
bronchial epithelial cells in vitro. Pretreatment for 4 h with different
doses of QF (QF-L, 0.1 mg/mL; QF-M, 0.5 mg/mL; QF-H,
2.5 mg/mL) was performed, followed by 10 ng/mL TNF-α stimulation
for 6 h. The positive control, Dex (1 μmol/L), and the medium and
high-dose QF signiﬁcantly suppressed IL-6 and IL-8 expression
(Fig. 2A, B) and NF-κB activation compared to the model group
(Po0.05 and Po0.01, Fig. 2C). However, the low dose QF had no
inhibitory effect. To verify the effect of QF-mediated inhibition of NF-
κB, western blotting was used to determine whether QF inhibited TNF-
α stimulated IκB-α degradation. As shown in Fig. 2D, IκB-α
degradation induced by TNF-α is suppressed by QF in a dose-
dependent manner. These results demonstrate the anti-inﬂammatory
effects of QF at the cellular level.
3.3. Quantitative analysis of anti-inﬂammatory ingredients
To clarify the content of the anti-inﬂammatory ingredients, UPLC/
Q-TOF-MS was used to identify the amount of arctiin (ATG-4-
glucoside), SPA, CGA and CLA derivatives in QF (Fig. 3).
Compared to CGA (2.18 mg/mL) and SPA (0.35 mg/mL), the
amount of ATG-4-glucoside (29.94 mg/mL) and total CLA deri-
vatives (50.65 mg/mL), including CLA (22.09 mg/mL), deoxy-
cholic acid (11.95 mg/mL), glycocholic acid (11.94 mg/mL) and
deoxyglycocholic acid (4.67 mg/mL), are higher in QF. ATG is the
primary metabolite after oral administration of arctiin15. Therefore,
ATG and CLA were predicted to play a major role in the anti-
inﬂammatory process. These compounds were derived from the
Fructus Arctii and Bovis Calculus, respectively.
3.4. Effects of four anti-inﬂammatory ingredients on candidate
gene expression
To investigate the possible anti-inﬂammatory mechanism, the
expression of critical genes of the PI3K/AKT and Ras/MAPK
pathways that was proved to be effective for QF-H group (data not
shown) was determined using quantitative RT-PCR. As shown in
Fig. 4, the mRNA expression of p38, Jnk, Erk, Fak, Pi3k, Ras,
Jak2 and Pkc were up-regulated greatly after TNF-α (10 ng/mL)
stimulation for 6 h in the model group. Compared to the model
Figure 1 Effects of QF administration on acute lung inﬂammation induced by P. aeruginosa. (A) HE staining of lung sections. The pictures were
taken under light microscopy at 100 magniﬁcation; effects of QF on the production of (B) TNF-α, (C) IL-8, (D) IL-6 and (E) RANTES in the
plasma and homogenized lung. The values are presented as mean7SD; *Po0.05, **Po0.01 and ***Po0.001 vs. model group (n¼5).
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all genes signiﬁcantly (Po0.05). However, the other compounds
had different inhibitory effects. The Ras/MAPK-related gene
expression of p38, Erk (Po0.05) and Ras (Po0.01) was
signiﬁcantly decreased with CLA pretreatment. CGA suppressed
the expression of p38, Jnk (Po0.05) and Pi3k (Po0.01).
Furthermore, SPA inhibited the expression of p38, Jnk, Erk, Ras
(Po0.05) and Pi3k, Fak (Po0.05). These results indicated that
CLA only affected the Ras/MAPK pathway, but ATG, CGA and
SPA affected both the PI3K/AKT and Ras/MAPK pathways.
3.5. Synergistic effects of anti-inﬂammatory ingredients on
PI3K/AKT pathway
PI3K/AKT and Ras/MAPK pathways have similar functions and have
complex interactions16 p38 kinase-dependent MAPK has an activating
function for AKT17 and PI3K/AKT is activated by low-molecular-
weight GTP/GDP binding GTPases, such as Ras, to further regulate theexpression of NF-κB18. To elucidate the synergistic effect on PI3K/
AKT/NF-κB, the combination treatment of the above four ingredients
was detected by downstream NF-κB-dependent signal transduction
(Fig. 5). Treatment with ATG, CLA, CGA or SPA decreased NF-κB
dependent transcription (Po0.05). When ATG was combined with
CLA, CGA and SPA, or all together, the inhibition was greater than for
any one drug (Po0.01 and Po0.001). These results indicate that ATG
is the most important inhibitor of the PI3K/AKT pathway.
3.6. Intracellular MAPK proteins levels validation of p38, JNK,
and ERK
MAPK has three family members, p38, JNK and ERK. PI3K inhibitors
decrease the activity of the Ras/MAPK pathway19. The effects of single
or combination treatment with different inhibitors on p38, JNK and
ERK intracellular proteins levels in TNF-α (10 ng/mL) stimulated
BEAS-2B cells were validated by ELISA. As shown in Fig. 6,
treatment with ATG alone signiﬁcantly suppressed the levels of p38,
Figure 2 Effects of QF in TNF-α stimulated BEAS-2B cells. (A) IL-6 expression and (B) IL-8 expression determined by ELISA; (C) NF-κB
activation detected by luciferase activity analysis; (D) IκB-α protein degradation analyzed by western blot. The values shown are mean7SD of
5 independent experiments; *Po0.05 and **Po0.01 vs. model group (n¼5).
Figure 3 Base peak intensity chromatogram in negative ion modes for QF.
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JNK (Po0.05). CLA reduced p38 and ERK (Po0.05) and SPA only
down-regulated the p38 level (Po0.01). For paired applications, the
synergistic effect of ATG combined with CLA suppressed the p38 and
ERK levels (Po0.001), whereas ATG combined with CGA or SPA
primarily affected the p38 and JNK levels (Po0.001).3.7. Target docking of active ingredients and anti-inﬂammatory
network analysis
To explore potential protein targets, a pharmacophore matching
platform, PharmMapper server, was utilized for target docking inthe PI3K/AKT and Ras/MAPK pathways. Molecular docking
validation was performed with AutoDock 4.0, providing further
detailed information for the representational ligands and regulated
targets, including ATG for PDK1 (7.24 kcal/mol) and JNK
(8.99 kcal/mol), CLA for FGFR (8.16 kcal/mol) and MEK
(9.86 kcal/mol), and CGA for Ras (7.16 kcal/mol), HSPA
(8.06 kcal/mol) and Rac (6.24 kcal/mol), which showed
higher scores for the PI3K/AKT and Ras/MAPK pathways
identifying them as potential targets. However, SPA for PDK1
(5.10 kcal/mol), FGFR (5.38 kcal/mol), Ras (4.39 kcal/
mol) and Rac (5.21 kcal/mol) had a lower binding energy and
were omitted from further analysis. The detail interaction informa-
tion of the key targets and related compound is shown in Fig. 7.
Figure 4 Effects of anti-inﬂammatory compounds from QF on gene expression in TNF-α stimulated BEAS-2B cells. The mRNA expression of
p38 (A), Jnk (B), Erk (C), Fak (D), Pi3k (E), Ras (F), Jak2 (G) and Pkc (H) was quantiﬁed by real-time PCR. Relative expression levels of the
genes were normalized to β-actin as an internal reference. The results are expressed as mean7 SD from 3 independent experiments; *Po0.05 and
**Po0.01 vs. model group (n¼3).
Figure 5 Effects of anti-inﬂammatory compounds from QF on
NF-κB activation in TNF-α stimulated BEAS-2B cells. ATG, CLA,
CGA and SPA were administered at 50 μmol/L when used alone,
25 μmol/L for paired combinations, and 12.5 μmol/L for combinations
of 4 drugs. The values shown are mean7SD of 4 independent
experiments; *Po0.05, **Po0.01 and ***Po0.001 vs. group treated
with TNF-α in the absence of drugs (n¼6).
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inﬂammatory network for QF and the PI3K/AKT and Ras/MAPK
pathways is summarized in Fig. 7.4. Discussion
P. aeruginosa–induced pneumonia is a complex process. First,
large numbers of thalli aggregating in the air way utilize ﬂagellum,ﬁmbriae, and polysaccharides on the membrane surface to adhere
to respiratory epithelia20,21. Then, the immune response of the host
is activated via invasion of the type III secretory protein, quorum-
sensing system, pyocyanin, LPS and other virulence factors.
Consequently, cytokines, chemotactic factors and other inﬂamma-
tory mediators are produced by host cells, which recruit and
activate macrophages, neutrophilic granulocytes, and T cells,
resulting in severe lung injury and mortality22–24. In this study,
we established a mouse acute pneumonia model with P. aerugi-
nosa and the protective effects of QF were estimated by evaluating
the expression of inﬂammatory mediators and the histopathologi-
cal condition. The results indicate that pretreatment with QF
signiﬁcantly inhibits the release of cytokines (TNF-α, IL-6) and
chemokines (IL-8, RANTES), reduces leukocytes recruitment into
inﬂamed tissues, ameliorates pulmonary edema and necrosis, and
promotes the survival of mice.
PI3K/AKT and Ras/MAPK are two important pathways for cell
membrane receptor signal transduction, which are involved in both
the inﬂammatory and immune response25, 26. LPS activates PKC
and initiates pro-inﬂammatory signals, such as FAK and Ras27.
FAK, a protein tyrosine kinase, can activate PI3K and MAPK to
regulate the expression of cytokines in the immune and inﬂam-
matory responses28,29. Furthermore, Ras is a GTPase, which
activates ERK and p38 to regulate the generation of inﬂammatory
factors30. By contrast, after binding to membrane receptors or
activating JAK, cytokines and other growth factor can activate
PI3K and MAPKs to regulate the proliferation and differentiation
of cells and the expression of pro-inﬂammatory factors31. The pro-
inﬂammatory factor TNF-α is not only a basic factor of the
inﬂammatory response, but it also acts on Gram-negative bacteria
through a positive feedback pathway and synergistically enhances
the infection32. In this study, cultured BEAS-2B cells induced with
TNF-α were selected for the inﬂammation model to assess the anti-
Qingfei Xiaoyan Wan, a traditional Chinese medicine formula, ameliorates Pseudomonas aeruginosa–induced acute 219inﬂammatory effect of QF in vitro. Four candidate compounds
from QF were then selected to determine the synergistic anti-
inﬂammatory mechanisms.Figure 6 Effects of anti-inﬂammatory compounds from QF on the
intracellular protein expressions of (A) p38, (B) JNK, and (C) ERK in
BEAS-2B cells. ATG, CLA, CGA, and SPA were administered at
50 μmol/L when used alone, 25 μmol/L for paired combinations, and
12.5 μmol/L for combinations of 4 drugs. The cells were lysed after drug
and TNF-α stimulation, and the cell lysates were analyzed by ELISA for
p38, JNK, and ERK levels. The values shown are mean 7SD of
6 independent experiments; *Po0.05, **Po0.01 and ***Po0.001 vs.
group treated with TNF-α in the absence of drugs (n¼6).
Figure 7 The scheme of the proposed network anti-inﬂammatory mATG is a representative dibenzyl butyrolactone lignan with
anti-inﬂammatory, anti-viral, anti-tumor, and Ca2þ antagonist
activities33. Its anti-inﬂammatory mechanisms include suppression
of the overproduction of NO by inhibiting the JAK-STAT signal
pathway in LPS-stimulated macrophages34,35 inhibition of AKT
phosphorylation and amelioration of inﬂammation by inhibiting the
PI3K/AKT pathway36,37 regulation of the activation of MAP kinases,
leading to AP-1 inactivation and the production of TNF-α38. In this
study, ATG was predicted target to PDK1 and downregulate the
phosphorylation of AKT and PKC, and further affect the expression of
the downstream genes, NF-κB and MAP kinases.
CGA signiﬁcantly inhibits the expression of COX-2 and iNOS,
attenuates inﬂammation-related markers, such as IL-1β, TNF-α,
IL-6, and ninjurin1 (Ninj1), abolishes the phosphorylation of Akt,
p38, ERK, and down regulates a receptor activator of the NF-κB
ligand induced nuclear factor of activated T cells c1 (NFATc1)
expression39,40. Additionally, the effects of CGA against LPS-
induced inﬂammation may be due to its ability to attenuate the
TLR4-mediated NF-κB signaling pathway41. In this study CGA
has been suggested to bind to the Ras protein, and when combined
with ATG affects the p38 and ERK pathways. These results were
consistent with previous reports.
In addition, the mechanism of the anti-inﬂammatory effects of
CLA and SPA for the suppression of TNF-α and IL-1β expression
via NF-κB was shown in previous studies42,43. In this study, CLA
simultaneously targeted the upstream protein FGFR and the
downstream protein MEK of the Ras/MAPK pathway, which
was speculated ﬁrstly. When combined with ATG, the effect also
occurred on the p38 and ERK sub-pathway. SPA has a smaller
molecular structure and the binding activities were also weaker.
Furthermore, because of its low content, SPA did not play a major
role in the overall anti-inﬂammatory effect.
In summary, a network mechanism of several ingredients was
identiﬁed from QF and mutual suppression was demonstrated on
the regulation of primary intracellular immune response to
ameliorate acute pneumonia induced by P. aeruginosa. ATG
was the principal ingredient responsible for the anti-
inﬂammatory effect both on the PI3K/AKT and Ras/MAPK
pathways. The other ingredients, CLA, and CGA, enhanced theechanisms for QF in the PI3K/AKT and Ras/MAPK pathways.
Yuanyuan Hou et al.220actions of ATG and showed synergistic NF-κB inactivation
effects, possibly via the Ras/MAPK signal pathway.Acknowledgments
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